Glaucoma innovation for end of 2010

Article

The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010

The French EyeOP1 medical device, from EyeTechCare, is a novel and non-invasive treatment for glaucoma that is based on the use of high-intensity focused ultrasound (HIFUs). The product is set to become available at the end of 2010.

HIFU technology allows ambulatory treatment, ensuring it is targeted and non-operator dependent, as well as limiting the cost and the risk for the patient. EyeOP1 will be on the market in late 2010 or early 2011.

The product recently won first prize in the 2010 Innovative Medical Technology competition organized by France's Alliance for Biological and Medical Engineering (Alliance pour le Génie Biologique et Médical – AGBM). The competition is open to small and medium-sized companies developing products that have the potential to bring major advances for the healthcare system.

“We were really taken with the technology developed by EyeTechCare, since it brings the hope of a solution to a worldwide public health problem,” explained the President of the IMT jury, Mathias Fink, a member of the French Academy of Sciences and the Collège de France. “Furthermore, EyeTechCare has succeeded in developing this device in less than two years and will soon offer medical practitioners an alternative therapeutic approach for the treatment of glaucoma.”

EyeTechCare expects to confirm the preliminary results of the device’s efficacy by launching it onto the market towards the end of 2010 or early in 2011 and by embarking on a multi-center international study between 2011 and 2013. This study will enable clinical data to be acquired on a large number of patients and over a sufficient period of time.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
(Image credit: Ophthalmology Times Europe) AGS 2025: Clemens Strohmaier, PhD, on improving aqueous humour outflow following excimer laser trabeculostomy
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
© 2025 MJH Life Sciences

All rights reserved.